Vascular endothelial growth factor receptor-2 in breast cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 1, 2010, Pages 108-121

  Guo, Shanchun ^a   Colbert, Laronna S ^a   Fuller, Miles ^a   Zhang, Yuanyuan ^a   Gonzalez Perez, Ruben R ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

Autocrine paracrine loop; Breast cancer; Leptin; Tumor angiogenesis; VEGF; VEGFR 2

Indexed keywords

ACETYL 11 OXO BETA BOSWELLIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOKINE; DNA VACCINE; ESTROGEN; GROWTH FACTOR; HISTONE DEACETYLASE INHIBITOR; LEPTIN; MONOCLONAL ANTIBODY IMC 1C11; NOTCH RECEPTOR; PEGYLATED LEPTIN PEPTIDE RECEPTOR ANTAGONIST 2; SCC S 2; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG TARGETING; EPIGENETICS; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; BREAST NEOPLASMS; CELL SURVIVAL; EPIGENESIS, GENETIC; FEMALE; HUMANS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MAMMALIA;

EID: 77953809510     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.04.004     Document Type: Review

References (227)

1. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
2. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
3. Shibuya M., Yamaguchi S., Yamane A., Ikeda T., Tojo A., Matsushime H., Sato M. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5:519-524.
4. Matthews W., Jordan C.T., Gavin M., Jenkins N.A., Copeland N.G., Lemischka I.R. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:9026-9030.
5. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 1993, 72:835-846.
6. Terman B.I., Carrion M.E., Kovacs E., Rasmussen B.A., Eddy R.L., Shows T.B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991, 6:1677-1683.
7. Pajusola K., Aprelikova O., Korhonen J., Kaipainen A., Pertovaara L., Alitalo R., Alitalo K. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res. 1992, 52:5738-5743.
8. Hannum C., Culpepper J., Campbell D., McClanahan T., Zurawski S., Bazan J.F., Kastelein R., Hudak S., Wagner J., Mattson J., et al. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994, 368:643-648.
9. Jussila L., Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol. Rev. 2002, 82:673-700.
10. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top Microbiol. Immunol. 1999, 237:1-30.
11. Kabrun N., Buhring H.J., Choi K., Ullrich A., Risau W., Keller G. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 1997, 124:2039-2048.
12. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376:66-70.
13. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 2006, 39:469-478.
14. Laakkonen P., Waltari M., Holopainen T., Takahashi T., Pytowski B., Steiner P., Hicklin D., Persaud K., Tonra J.R., Witte L., Alitalo K. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007, 67:593-599.
15. Lohela M., Bry M., Tammela T., Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21:154-165.
16. Rappold I., Ziegler B.L., Kohler I., Marchetto S., Rosnet O., Birnbaum D., Simmons P.J., Zannettino A.C., Hill B., Neu S., Knapp W., Alitalo R., Alitalo K., Ullrich A., Kanz L., Buhring H.J. Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood 1997, 90:111-125.
17. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
18. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
19. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 2006, 312:549-560.
20. Terman B.I., Dougher-Vermazen M., Carrion M.E., Dimitrov D., Armellino D.C., Gospodarowicz D., Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992, 187:1579-1586.
21. Oelrichs R.B., Reid H.H., Bernard O., Ziemiecki A., Wilks A.F. NYK/FLK-1: a putative receptor protein tyrosine kinase isolated from E10 embryonic neuroepithelium is expressed in endothelial cells of the developing embryo. Oncogene 1993, 8:11-18.
22. Sarzani R., Arnaldi G., De Pirro R., Moretti P., Schiaffino S., Rappelli A. A novel endothelial tyrosine kinase cDNA homologous to platelet-derived growth factor receptor cDNA. Biochem. Biophys. Res. Commun. 1992, 186:706-714.
23. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 1994, 269:26988-26995.
24. Barleon B., Totzke F., Herzog C., Blanke S., Kremmer E., Siemeister G., Marme D., Martiny-Baron G. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J. Biol. Chem. 1997, 272:10382-10388.
25. Davis-Smyth T., Chen H., Park J., Presta L.G., Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 1996, 15:4919-4927.
26. Shinkai A., Ito M., Anazawa H., Yamaguchi S., Shitara K., Shibuya M. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J. Biol. Chem. 1998, 273:31283-31288.
27. Tanaka K., Yamaguchi S., Sawano A., Shibuya M. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn. J. Cancer Res. 1997, 88:867-876.
28. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U. S. A. 1998, 95:548-553.
29. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15:1751.
30. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Buttner M., Rziha H.J., Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 1999, 18:363-374.
31. Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998, 273:31273-31282.
32. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci. 2003, 94:751-756.
33. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.M., Shibuya M., Collen D., Conway E.M., Carmeliet P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 2003, 9:936-943.
34. Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S., Yla-Herttuala S., Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 2001, 7:199-205.
35. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 1994, 269:25646-25654.
36. Huang K., Andersson C., Roomans G.M., Ito N., Claesson-Welsh L. Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers. Int. J. Biochem. Cell Biol. 2001, 33:315-324.
37. Dixelius J., Makinen T., Wirzenius M., Karkkainen M.J., Wernstedt C., Alitalo K., Claesson-Welsh L. Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 2003, 278:40973-40979.
38. Mac Gabhann F., Popel A.S. Dimerization of VEGF receptors and implications for signal transduction: a computational study. Biophys. Chem. 2007, 128:125-139.
39. Neagoe P.E., Lemieux C., Sirois M.G. Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer. J. Biol. Chem. 2005, 280:9904-9912.
40. Olsson A.K., Dimberg A., Kreuger J., Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 2006, 7:359-371.
41. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front. Biosci. 2006, 11:818-829.
42. Kliche S., Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life 2001, 52:61-66.
43. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 2003, 31:1171-1177.
44. Solowiej J., Bergqvist S., McTigue M.A., Marrone T., Quenzer T., Cobbs M., Ryan K., Kania R.S., Diehl W., Murray B.W. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 2009, 48:7019-7031.
45. Singh A.J., Meyer R.D., Band H., Rahimi N. The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol. Biol. Cell 2005, 16:2106-2118.
46. Takahashi T., Shibuya M. The 230kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997, 14:2079-2089.
47. Abedi H., Zachary I. Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells. J. Biol. Chem. 1997, 272:15442-15451.
48. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60:203-212.
49. Matsumoto T., Bohman S., Dixelius J., Berge T., Dimberg A., Magnusson P., Wang L., Wikner C., Qi J.H., Wernstedt C., Wu J., Bruheim S., Mugishima H., Mukhopadhyay D., Spurkland A., Claesson-Welsh L. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J. 2005, 24:2342-2353.
50. Tahir S.A., Park S., Thompson T.C. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate cancer and endothelial cells. Cancer Biol. Ther. 2009, 8.
51. Xiong Y., Huo Y., Chen C., Zeng H., Lu X., Wei C., Ruan C., Zhang X., Hu Z., Shibuya M., Luo J. Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathways. J. Biol. Chem. 2009, 284:23217-23224.
52. Dayanir V., Meyer R.D., Lashkari K., Rahimi N. Identification of tyrosine residues in vascular endothelial growth factor receptor-2/FLK-1 involved in activation of phosphatidylinositol 3-kinase and cell proliferation. J. Biol. Chem. 2001, 276:17686-17692.
53. Issbrucker K., Marti H.H., Hippenstiel S., Springmann G., Voswinckel R., Gaumann A., Breier G., Drexler H.C., Suttorp N., Clauss M. p38 MAP kinase-a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. 2003, 17:262-264.
54. Andre T., Kotelevets L., Vaillant J.C., Coudray A.M., Weber L., Prevot S., Parc R., Gespach C., Chastre E. Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int. J. Cancer 2000, 86:174-181.
55. Wu Y., Hooper A.T., Zhong Z., Witte L., Bohlen P., Rafii S., Hicklin D.J. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int. J. Cancer 2006, 119:1519-1529.
56. Mercurio A.M., Bachelder R.E., Bates R.C., Chung J. Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin. Semin. Cancer Biol. 2004, 14:115-122.
57. Bachelder R.E., Crago A., Chung J., Wendt M.A., Shaw L.M., Robinson G., Mercurio A.M. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001, 61:5736-5740.
58. Aesoy R., Sanchez B.C., Norum J.H., Lewensohn R., Viktorsson K., Linderholm B. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells. Mol. Cancer Res. 2008, 6:1630-1638.
59. Svensson S., Jirstrom K., Ryden L., Roos G., Emdin S., Ostrowski M.C., Landberg G. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005, 24:4370-4379.
60. Weigand M., Hantel P., Kreienberg R., Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 2005, 8:197-204.
61. Gonzalez R.R., Cherfils S., Escobar M., Yoo J.H., Carino C., Styer A.K., Sullivan B.T., Sakamoto H., Olawaiye A., Serikawa T., Lynch M.P., Rueda B.R. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J. Biol. Chem. 2006, 281:26320-26328.
62. Rene Gonzalez R., Watters A., Xu Y., Singh U.P., Mann D.R., Rueda B.R., Penichet M.L. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. Breast Cancer Res. 2009, 11:R36.
63. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., Madge L.A., Schechner J.S., Schwabb M.B., Polverini P.J., Flores-Riveros J.R. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686.
64. Carino C., Olawaiye A.B., Cherfils S., Serikawa T., Lynch M.P., Rueda B.R., Gonzalez R.R. Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. Int. J. Cancer 2008, 123:2782-2790.
65. Dias S., Hattori K., Heissig B., Zhu Z., Wu Y., Witte L., Hicklin D.J., Tateno M., Bohlen P., Moore M.A., Rafii S. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10857-10862.
66. Steiner H., Berger A.P., Godoy-Tundidor S., Bjartell A., Lilja H., Bartsch G., Hobisch A., Culig Z. An autocrine loop for vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur. J. Cancer 2004, 40:1066-1072.
67. Brown L.F., Berse B., Jackman R.W., Tognazzi K., Guidi A.J., Dvorak H.F., Senger D.R., Connolly J.L., Schnitt S.J. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum. Pathol. 1995, 26:86-91.
68. Kranz A., Mattfeldt T., Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int. J. Cancer 1999, 84:293-298.
69. Ryden L., Linderholm B., Nielsen N.H., Emdin S., Jonsson P.E., Landberg G. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res. Treat. 2003, 82:147-154.
70. Ryden L., Stendahl M., Jonsson H., Emdin S., Bengtsson N.O., Landberg G. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res. Treat. 2005, 89:135-143.
71. Giatromanolaki A., Koukourakis M.I., Sivridis E., Chlouverakis G., Vourvouhaki E., Turley H., Harris A.L., Gatter K.C. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur. J. Clin. Invest. 2007, 37:878-886.
72. Higgins K.J., Abdelrahim M., Liu S., Yoon K., Safe S. Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. Biochem. Biophys. Res. Commun. 2006, 345:292-301.
73. Spannuth W.A., Nick A.M., Jennings N.B., Armaiz-Pena G.N., Mangala L.S., Danes C.G., Lin Y.G., Merritt W.M., Thaker P.H., Kamat A.A., Han L.Y., Tonra J.R., Coleman R.L., Ellis L.M., Sood A.K. Functional significance of VEGFR-2 on ovarian cancer cells. Int. J. Cancer 2009, 124:1045-1053.
74. Tanno S., Ohsaki Y., Nakanishi K., Toyoshima E., Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 2004, 46:11-19.
75. Fox S.B., Generali D.G., Harris A.L. Breast tumour angiogenesis. Breast Cancer Res. 2007, 9:216.
76. Nakopoulou L., Stefanaki K., Panayotopoulou E., Giannopoulou I., Athanassiadou P., Gakiopoulou-Givalou H., Louvrou A. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation. Hum. Pathol. 2002, 33:863-870.
77. Longatto-Filho A., Pinheiro C., Martinho O., Moreira M.A., Ribeiro L.F., Queiroz G.S., Schmitt F.C., Baltazar F., Reis R.M. Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer 2009, 9:212.
78. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995, 55:3964-3968.
79. Gockel I., Moehler M., Frerichs K., Drescher D., Trinh T.T., Duenschede F., Borschitz T., Schimanski K., Biesterfeld S., Herzer K., Galle P.R., Lang H., Junginger T., Schimanski C.C. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. Oncol. Rep. 2008, 20:845-850.
80. Badalian G., Derecskei K., Szendroi A., Szendroi M., Timar J. EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer. Anticancer Res. 2007, 27:889-894.
81. Xia G., Kumar S.R., Hawes D., Cai J., Hassanieh L., Groshen S., Zhu S., Masood R., Quinn D.I., Broek D., Stein J.P., Gill P.S. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J. Urol. 2006, 175:1245-1252.
82. Puputti M., Tynninen O., Sihto H., Blom T., Maenpaa H., Isola J., Paetau A., Joensuu H., Nupponen N.N. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol. Cancer Res. 2006, 4:927-934.
83. Kim A.L.R.D., Aucejo F., et al. Vascular endothelial growth factor receptor 2 (VEGFr2) expression and recurrence of hepatocellular carcinoma following liver transplantation: the Cleveland Clinic experience. J. Clin. Oncol. 26 (15) (Supplement) 2008, S4594.
84. Ashikari-Hada S., Habuchi H., Kariya Y., Kimata K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. J. Biol. Chem. 2005, 280:31508-31515.
85. Miao H.Q., Lee P., Lin H., Soker S., Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J. 2000, 14:2532-2539.
86. Tzima E., Irani-Tehrani M., Kiosses W.B., Dejana E., Schultz D.A., Engelhardt B., Cao G., DeLisser H., Schwartz M.A. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 2005, 437:426-431.
87. Carmeliet P., Lampugnani M.G., Moons L., Breviario F., Compernolle V., Bono F., Balconi G., Spagnuolo R., Oosthuyse B., Dewerchin M., Zanetti A., Angellilo A., Mattot V., Nuyens D., Lutgens E., Clotman F., de Ruiter M.C., Gittenberger-de Groot A., Poelmann R., Lupu F., Herbert J.M., Collen D., Dejana E. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999, 98:147-157.
88. Somanath P.R., Malinin N.L., Byzova T.V. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12:177-185.
89. Robinson S.D., Reynolds L.E., Kostourou V., Reynolds A.R., da Silva R.G., Tavora B., Baker M., Marshall J.F., Hodivala-Dilke K.M. Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J. Biol. Chem. 2009, 284:33966-33981.
90. Germain M., De Arcangelis A., Robinson S.D., Baker M., Tavora B., D'Amico G., Silva R., Kostourou V., Reynolds L.E., Watson A., Jones J.L., Georges-Labouesse E., Hodivala-Dilke K. Genetic ablation of the alpha 6-integrin subunit in Tie1Cre mice enhances tumour angiogenesis. J. Pathol. 2010, 220(3):370-381.
91. Zhang X., Kazerounian S., Duquette M., Perruzzi C., Nagy J.A., Dvorak H.F., Parangi S., Lawler J. Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J. 2009, 23:3368-3376.
92. Zhang Z., Neiva K.G., Lingen M.W., Ellis L.M., Nor J.E. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ., J. Pathol. 2010, 17(3):499-512.
93. Bruns A.F., Bao L., Walker J.H., Ponnambalam S. VEGF-A-stimulated signalling in endothelial cells via a dual receptor tyrosine kinase system is dependent on co-ordinated trafficking and proteolysis. Biochem. Soc. Trans. 2009, 37:1193-1197.
94. A.F. Bruns, S.P. Herbert, A.F. Odell, H.M. Jopling, N.M. Hooper, I.C. Zachary, J.H. Walker, S. Ponnambalam, Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis, Traffic 11 161-174.
95. Scott A., Mellor H. VEGF receptor trafficking in angiogenesis. Biochem. Soc. Trans. 2009, 37:1184-1188.
96. Patterson C., Perrella M.A., Hsieh C.M., Yoshizumi M., Lee M.E., Haber E. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J. Biol. Chem. 1995, 270:23111-23118.
97. Ronicke V., Risau W., Breier G. Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter. Circ. Res. 1996, 79:277-285.
98. Wu Y., Patterson C. The human KDR/flk-1 gene contains a functional initiator element that is bound and transactivated by TFII-I. J. Biol. Chem. 1999, 274:3207-3214.
99. Patterson C., Wu Y., Lee M.E., DeVault J.D., Runge M.S., Haber E. Nuclear protein interactions with the human KDR/flk-1 promoter in vivo. Regulation of Sp1 binding is associated with cell type-specific expression. J. Biol. Chem. 1997, 272:8410-8416.
100. Hata Y., Duh E., Zhang K., Robinson G.S., Aiello L.P. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence. J. Biol. Chem. 1998, 273:19294-19303.
101. Urbich C., Stein M., Reisinger K., Kaufmann R., Dimmeler S., Gille J. Fluid shear stress-induced transcriptional activation of the vascular endothelial growth factor receptor-2 gene requires Sp1-dependent DNA binding. FEBS Lett. 2003, 535:87-93.
102. Meissner M., Michailidou D., Stein M., Hrgovic I., Kaufmann R., Gille J. Inhibition of Rac1 GTPase downregulates vascular endothelial growth factor receptor-2 expression by suppressing Sp1-dependent DNA binding in human endothelial cells. Exp. Dermatol. 2009, 18:863-869.
103. Higgins K.J., Liu S., Abdelrahim M., Yoon K., Vanderlaag K., Porter W., Metz R.P., Safe S. Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins. Endocrinology 2006, 147:3285-3295.
104. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
105. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
106. Yamada Y., Watanabe M., Yamanaka M., Hirokawa Y., Suzuki H., Takagi A., Matsuzaki T., Sugimura Y., Yatani R., Shiraishi T. Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer. Cancer Sci. 2003, 94:536-539.
107. Kunizaki M., Hamamoto R., Silva F.P., Yamaguchi K., Nagayasu T., Shibuya M., Nakamura Y., Furukawa Y. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer Res. 2007, 67:10759-10765.
108. Kim J.Y., Hwang J.H., Zhou W., Shin J., Noh S.M., Song I.S., Lee S.H., Kim J. The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. Epigenetics 2009, 4:313-321.
109. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
110. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
111. Jenuwein T. Re-SET-ting heterochromatin by histone methyltransferases. Trends Cell Biol. 2001, 11:266-273.
112. Wade P.A., Wolffe A.P. Histone acetyltransferases in control. Curr. Biol. 1997, 7:R82-R84.
113. Kuo M.H., Allis C.D. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998, 20:615-626.
114. G. M. Barr, K. Gately, N. Al-Sarraf, G.P. Pidgeon and K.J. O'Byrne, VEGF and the epigenetic regulation of its receptors in non-small cell lung cancer, Lung Cancer 63(Supplement 1), (2009) S1, S1-S38.
115. Bray S.J. Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 2006, 7:678-689.
116. Phng L.K., Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev. Cell 2009, 16:196-208.
117. Roca C., Adams R.H. Regulation of vascular morphogenesis by Notch signaling. Genes Dev. 2007, 21:2511-2524.
118. Stylianou S., Clarke R.B., Brennan K. Aberrant activation of notch signaling in human breast cancer. Cancer Res. 2006, 66:1517-1525.
119. Imatani A., Callahan R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene 2000, 19:223-231.
120. Soares R., Balogh G., Guo S., Gartner F., Russo J., Schmitt F. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol. Endocrinol. 2004, 18:2333-2343.
121. Kovall R.A. More complicated than it looks: assembly of Notch pathway transcription complexes. Oncogene 2008, 27:5099-5109.
122. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: cell fate control and signal integration in development. Science 1999, 284:770-776.
123. Benedito R., Roca C., Sorensen I., Adams S., Gossler A., Fruttiger M., Adams R.H. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137:1124-1135.
124. Williams C.K., Li J.L., Murga M., Harris A.L., Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006, 107:931-939.
125. Taylor K.L., Henderson A.M., Hughes C.C. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc. Res. 2002, 64:372-383.
126. Lee C.W., Raskett C.M., Prudovsky I., Altieri D.C. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res. 2008, 68:5273-5281.
127. Lee C.W., Simin K., Liu Q., Plescia J., Guha M., Khan A., Hsieh C.C., Altieri D.C. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res. 2008, 10:R97.
128. Monsalve E., Ruiz-Garcia A., Baladron V., Ruiz-Hidalgo M.J., Sanchez-Solana B., Rivero S., Garcia-Ramirez J.J., Rubio A., Laborda J., Diaz-Guerra M.J. Notch1 upregulates LPS-induced macrophage activation by increasing NF-kappaB activity. Eur. J. Immunol. 2009, 39:2556-2570.
129. Ferreira A.M., Westers H., Albergaria A., Seruca R., Hofstra R.M. Estrogens, MSI and Lynch syndrome-associated tumors. Biochim. Biophys. Acta 2009, 1796:194-200.
130. Russo J., Russo I.H. The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol. 2006, 102:89-96.
131. Santen R., Cavalieri E., Rogan E., Russo J., Guttenplan J., Ingle J., Yue W. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects. Ann. N. Y. Acad. Sci. 2009, 1155:132-140.
132. Kim K.H., Bender J.R. Rapid, estrogen receptor-mediated signaling: why is the endothelium so special?. Sci. STKE 2005, 2005:e28.
133. Rubanyi G.M., Johns A., Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul. Pharmacol. 2002, 38:89-98.
134. Simoncini T., Mannella P., Fornari L., Caruso A., Varone G., Genazzani A.R. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004, 69:537-542.
135. Suzuma I., Mandai M., Takagi H., Suzuma K., Otani A., Oh H., Kobayashi K., Honda Y. 17 Beta-estradiol increases VEGF receptor-2 and promotes DNA synthesis in retinal microvascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 1999, 40:2122-2129.
136. Tanemura M., Miyamoto N., Mandai M., Kamizuru H., Ooto S., Yasukawa T., Takahashi M., Honda Y. The role of estrogen and estrogen receptorbeta in choroidal neovascularization. Mol. Vis. 2004, 10:923-932.
137. Higgins K.J., Liu S., Abdelrahim M., Vanderlaag K., Liu X., Porter W., Metz R., Safe S. Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins. Mol. Endocrinol. 2008, 22:388-402.
138. Kremer C., Breier G., Risau W., Plate K.H. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res. 1997, 57:3852-3859.
139. Gerber H.P., Condorelli F., Park J., Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 1997, 272:23659-23667.
140. Arroyo A.G., Iruela-Arispe M.L. Extracellular matrix, inflammation, and the angiogenic response. Cardiovasc. Res. 2010, 10.
141. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23:1011-1027.
142. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
143. Barleon B., Siemeister G., Martiny-Baron G., Weindel K., Herzog C., Marme D. Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res. 1997, 57:5421-5425.
144. Patterson C., Perrella M.A., Endege W.O., Yoshizumi M., Lee M.E., Haber E. Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J. Clin. Invest. 1996, 98:490-496.
145. Giraudo E., Primo L., Audero E., Gerber H.P., Koolwijk P., Soker S., Klagsbrun M., Ferrara N., Bussolino F. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J. Biol. Chem. 1998, 273:22128-22135.
146. Sainson R.C., Johnston D.A., Chu H.C., Holderfield M.T., Nakatsu M.N., Crampton S.P., Davis J., Conn E., Hughes C.C. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 2008, 111:4997-5007.
147. Han K.Y., Kim C.W., Lee T.H., Son Y., Kim J. CCL23 up-regulates expression of KDR/Flk-1 and potentiates VEGF-induced proliferation and migration of human endothelial cells. Biochem. Biophys. Res. Commun. 2009, 382:124-128.
148. Hu X., Juneja S.C., Maihle N.J., Cleary M.P. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J. Natl. Cancer Inst. 2002, 94:1704-1711.
149. Pischon T., Nothlings U., Boeing H. Obesity and cancer. Proc. Nutr. Soc. 2008, 67:128-145.
150. Cleary M.P., Maihle N.J. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc. Soc. Exp. Biol. Med. 1997, 216:28-43.
151. A. Ray, M.P. Cleary, Leptin as a potential therapeutic target for breast cancer prevention and treatment, Expert. Opin. Ther. Targets 14 443-451.
152. Laud K., Gourdou I., Pessemesse L., Peyrat J.P., Djiane J. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line. Mol. Cell Endocrinol. 2002, 188:219-226.
153. Tessitore L., Vizio B., Jenkins O., De Stefano I., Ritossa C., Argiles J.M., Benedetto C., Mussa A. Leptin expression in colorectal and breast cancer patients. Int. J. Mol. Med. 2000, 5:421-426.
154. Klurfeld D.M., Welch C.B., Lloyd L.M., Kritchevsky D. Inhibition of DMBA-induced mammary tumorigenesis by caloric restriction in rats fed high-fat diets. Int. J. Cancer 1989, 43:922-925.
155. Cleary M.P., Juneja S.C., Phillips F.C., Hu X., Grande J.P., Maihle N.J. Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp. Biol. Med. (Maywood) 2004, 229:182-193.
156. Cleary M.P., Phillips F.C., Getzin S.C., Jacobson T.L., Jacobson M.K., Christensen T.A., Juneja S.C., Grande J.P., Maihle N.J. Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res. Treat. 2003, 77:205-215.
157. Cioffi J.A., Shafer A.W., Zupancic T.J., Smith-Gbur J., Mikhail A., Platika D., Snodgrass H.R. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat. Med. 1996, 2:585-589.
158. Lollmann B., Gruninger S., Stricker-Krongrad A., Chiesi M. Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem. Biophys. Res. Commun. 1997, 238:648-652.
159. Tartaglia L.A. The leptin receptor. J. Biol. Chem. 1997, 272:6093-6096.
160. Akther A., Khan K.H., Begum M., Parveen S., Kaiser M.S., Chowdhury A.Z. Leptin: a mysterious hormone; its physiology and pathophysiology. Mymensingh Med. J. 2009, 18:S140-S144.
161. Minokoshi Y., Kim Y.B., Peroni O.D., Fryer L.G., Muller C., Carling D., Kahn B.B. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002, 415:339-343.
162. Beecken W.D., Kramer W., Jonas D. New molecular mediators in tumor angiogenesis. J. Cell. Mol. Med. 2000, 4:262-269.
163. Cirillo D., Rachiglio A.M., la Montagna R., Giordano A., Normanno N. Leptin signaling in breast cancer: an overview. J. Cell Biochem. 2008, 105:956-964.
164. Hausman G.J., Richardson R.L. Adipose tissue angiogenesis. J. Anim. Sci. 2004, 82:925-934.
165. Binai N.A., Damert A., Carra G., Steckelbroeck S., Lower J., Lower R., Wessler S. Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells. Int. J. Cancer 2010, 127:55-66.
166. Fiorio E., Mercanti A., Terrasi M., Micciolo R., Remo A., Auriemma A., Molino A., Parolin V., Di Stefano B., Bonetti F., Giordano A., Cetto G.L., Surmacz E. Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008, 8:305.
167. Soma D., Kitayama J., Yamashita H., Miyato H., Ishikawa M., Nagawa H. Leptin augments proliferation of breast cancer cells via transactivation of HER2. J. Surg. Res. 2008, 149:9-14.
168. Catalano S., Marsico S., Giordano C., Mauro L., Rizza P., Panno M.L., Ando S. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J. Biol. Chem. 2003, 278:28668-28676.
169. Hayes D.F., Miller K., Sledge G. Angiogenesis as targeted breast cancer therapy. Breast 2007, 16(Suppl 2):S17-S19.
170. Roy V., Perez E.A. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways. Breast Cancer Res. Treat. 2009, 116:31-38.
171. Shi W., Harris A.L. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J. Mammary Gland. Biol. Neoplasia 2006, 11:41-52.
172. Ellis L., Hammers H., Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009, 280:145-153.
173. Qian D.Z., Wang X., Kachhap S.K., Kato Y., Wei Y., Zhang L., Atadja P., Pili R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004, 64:6626-6634.
174. Liang Y., Brekken R.A., Hyder S.M. Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. Endocr. Relat. Cancer 2006, 13:905-919.
175. Weng D.E., Usman N. Angiozyme: a novel angiogenesis inhibitor. Curr. Oncol. Rep. 2001, 3:141-146.
176. Borgstrom P., Gold D.P., Hillan K.J., Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res. 1999, 19:4203-4214.
177. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
178. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367:576-579.
179. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
180. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., Dickler M., Overmoyer B.A., Reimann J.D., Sing A.P., Langmuir V., Rugo H.S. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005, 23:792-799.
181. Wedam S.B., Low J.A., Yang S.X., Chow C.K., Choyke P., Danforth D., Hewitt S.M., Berman A., Steinberg S.M., Liewehr D.J., Plehn J., Doshi A., Thomasson D., McCarthy N., Koeppen H., Sherman M., Zujewski J., Camphausen K., Chen H., Swain S.M. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. 2006, 24:769-777.
182. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003, 349:427-434.
183. Weigert G., Michels S., Sacu S., Varga A., Prager F., Geitzenauer W., Schmidt-Erfurth U. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br. J. Ophthalmol. 2008, 92:356-360.
184. Lu D., Kussie P., Pytowski B., Persaud K., Bohlen P., Witte L., Zhu Z. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J. Biol. Chem. 2000, 275:14321-14330.
185. Zhu Z., Rockwell P., Lu D., Kotanides H., Pytowski B., Hicklin D.J., Bohlen P., Witte L. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. 1998, 58:3209-3214.
186. Posey J.A., Ng T.C., Yang B., Khazaeli M.B., Carpenter M.D., Fox F., Needle M., Waksal H., LoBuglio A.F. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. 2003, 9:1323-1332.
187. Fong T.A., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X., Risau W., Ullrich A., Hirth K.P., McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59:99-106.
188. Fury M.G., Zahalsky A., Wong R., Venkatraman E., Lis E., Hann L., Aliff T., Gerald W., Fleisher M., Pfister D.G. A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest. New Drugs 2007, 25:165-172.
189. Ansiaux R., Dewever J., Gregoire V., Feron O., Jordan B.F., Gallez B. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat. Res. 2009, 172:584-591.
190. Banerjee S., Zvelebil M., Furet P., Mueller-Vieira U., Evans D.B., Dowsett M., Martin L.A. The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. Cancer Res. 2009, 69:4716-4723.
191. Beebe J.S., Jani J.P., Knauth E., Goodwin P., Higdon C., Rossi A.M., Emerson E., Finkelstein M., Floyd E., Harriman S., Atherton J., Hillerman S., Soderstrom C., Kou K., Gant T., Noe M.C., Foster B., Rastinejad F., Marx M.A., Schaeffer T., Whalen P.M., Roberts W.G. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63:7301-7309.
192. Kumar D., Gokhale P., Broustas C., Chakravarty D., Ahmad I., Kasid U. Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells. Oncogene 2004, 23:612-616.
193. Zhang C., Chakravarty D., Sakabe I., Mewani R.R., Boudreau H.E., Kumar D., Ahmad I., Kasid U.N. Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. Mol. Ther. 2006, 13:947-955.
194. Song W., Dong Z., Jin T., Mantellini M.G., Nunez G., Nor J.E. Cancer gene therapy with iCaspase-9 transcriptionally targeted to tumor endothelial cells. Cancer Gene Ther. 2008, 15:667-675.
195. Yan J., Jia R., Song H., Liu Y., Zhang L., Zhang W., Wang Y., Zhu Y., Yu J. A promising new approach of VEGFR2-based DNA vaccine for tumor immunotherapy. Immunol. Lett. 2009, 126:60-66.
196. Mannion M., Raeppel S., Claridge S., Zhou N., Saavedra O., Isakovic L., Zhan L., Gaudette F., Raeppel F., Deziel R., Beaulieu N., Nguyen H., Chute I., Beaulieu C., Dupont I., Robert M.F., Lefebvre S., Dubay M., Rahil J., Wang J., Ste-Croix H., Robert Macleod A., Besterman J.M., Vaisburg A. N-(4-(6, 7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazol i dine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19:6552-6556.
197. Pang X., Yi Z., Zhang X., Sung B., Qu W., Lian X., Aggarwal B.B., Liu M. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res. 2009, 69:5893-5900.
198. Carrillo de Santa Pau E., Arias F.C., Caso Pelaez E., Munoz Molina G.M., Sanchez Hernandez I., Muguruza Trueba I., Moreno Balsalobre R., Sacristan Lopez S., Gomez Pinillos A., del Val Toledo Lobo M. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer 2009, 115:1701-1712.
199. Sato H., Takeda Y. VEGFR2 expression and relationship between tumor neovascularization and histologic characteristics in oral squamous cell carcinoma. J. Oral. Sci. 2009, 51:551-557.
200. Chen H., Ye D., Xie X., Chen B., Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol. Oncol. 2004, 94:630-635.
201. Itakura J., Ishiwata T., Shen B., Kornmann M., Korc M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 2000, 85:27-34.
202. Stadler W.M., Cao D., Vogelzang N.J., Ryan C.W., Hoving K., Wright R., Karrison T., Vokes E.E. A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin. Cancer Res. 2004, 10:3365-3370.
203. Straume O., Akslen L.A. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis 2003, 6:295-301.
204. Lee J.H., Chun T., Park S.Y., Rho S.B. Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced angiogenesis in HUVECs. Biochim. Biophys. Acta 2008, 1783:1654-1662.
205. Chauvet C., Bois-Joyeux B., Berra E., Pouyssegur J., Danan J.L. The gene encoding human retinoic acid-receptor-related orphan receptor alpha is a target for hypoxia-inducible factor 1. Biochem. J. 2004, 384:79-85.
206. Razny U., Wator L., Polus A., Wan Y.J., Dyduch G., Tomaszewska R., Dembinska-Kiec A. Hepatocyte RXR alpha deletion in mice leads to inhibition of angiogenesis. Genes Nutr. 2009, 4:69-72.
207. Gaetano C., Catalano A., Illi B., Felici A., Minucci S., Palumbo R., Facchiano F., Mangoni A., Mancarella S., Muhlhauser J., Capogrossi M.C. Retinoids induce fibroblast growth factor-2 production in endothelial cells via retinoic acid receptor alpha activation and stimulate angiogenesis in vitro and in vivo. Circ. Res. 2001, 88:E38-E47.
208. Davis R., Singh K.P., Kurzrock R., Shankar S. Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol. Rep. 2009, 22:1473-1478.
209. Huang X., Brown C., Ni W., Maynard E., Rigby A.C., Oettgen P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006, 107:3153-3160.
210. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 2009, 284:6038-6042.
211. Fritz W.A., Lin T.M., Peterson R.E. The aryl hydrocarbon receptor (AhR) inhibits vanadate-induced vascular endothelial growth factor (VEGF) production in TRAMP prostates. Carcinogenesis 2008, 29:1077-1082.
212. Charboneau A., East L., Mulholland N., Rohde M., Boudreau N. Pbx1 is required for Hox D3-mediated angiogenesis. Angiogenesis 2005, 8:289-296.
213. Biscetti F., Gaetani E., Flex A., Straface G., Pecorini G., Angelini F., Stigliano E., Aprahamian T., Smith R.C., Castellot J.J., Pola R. Peroxisome proliferator-activated receptor alpha is crucial for iloprost-induced in vivo angiogenesis and vascular endothelial growth factor upregulation. J. Vasc. Res. 2009, 46:103-108.
214. Gerald D., Berra E., Frapart Y.M., Chan D.A., Giaccia A.J., Mansuy D., Pouyssegur J., Yaniv M., Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004, 118:781-794.
215. Teodoro J.G., Evans S.K., Green M.R. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med. 2007, 85:1175-1186.
216. Joung Y.H., Lim E.J., Lee M.Y., Park J.H., Ye S.K., Park E.U., Kim S.Y., Zhang Z., Lee K.J., Park D.K., Park T., Moon W.K., Yang Y.M. Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells. Exp. Mol. Med. 2005, 37:353-364.
217. Chen Z., Han Z.C. STAT3: a critical transcription activator in angiogenesis. Med. Res. Rev. 2008, 28:185-200.
218. Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J. Steroid. Biochem. Mol. Biol. 2008, 108:261-266.
219. Kuenen B.C., Giaccone G., Ruijter R., Kok A., Schalkwijk C., Hoekman K., Pinedo H.M. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin. Cancer Res. 2005, 11:6240-6246.
220. Xiong H.Q., Herbst R., Faria S.C., Scholz C., Davis D., Jackson E.F., Madden T., McConkey D., Hicks M., Hess K., Charnsangavej C.A., Abbruzzese J.L. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest. New Drugs 2004, 22:459-466.
221. Amino N., Ideyama Y., Yamano M., Kuromitsu S., Tajinda K., Samizu K., Hisamichi H., Matsuhisa A., Shirasuna K., Kudoh M., Shibasaki M. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin. Cancer Res. 2006, 12:1630-1638.
222. Drevs J., Siegert P., Medinger M., Mross K., Strecker R., Zirrgiebel U., Harder J., Blum H., Robertson J., Jurgensmeier J.M., Puchalski T.A., Young H., Saunders O., Unger C. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2007, 25:3045-3054.
223. Laurie S.A., Gauthier I., Arnold A., Shepherd F.A., Ellis P.M., Chen E., Goss G., Powers J., Walsh W., Tu D., Robertson J., Puchalski T.A., Seymour L. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 2008, 26:1871-1878.
224. Robertson J.D., Botwood N.A., Rothenberg M.L., Schmoll H.J. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin. Colorectal. Cancer 2009, 8:59-60.
225. Dineen S.P., Sullivan L.A., Beck A.W., Miller A.F., Carbon J.G., Mamluk R., Wong H., Brekken R.A. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 2008, 8:352.
226. Jones-Bolin S., Zhao H., Hunter K., Klein-Szanto A., Ruggeri B. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther. 2006, 5:1744-1753.
227. Ruggeri B., Singh J., Gingrich D., Angeles T., Albom M., Yang S., Chang H., Robinson C., Hunter K., Dobrzanski P., Jones-Bolin S., Pritchard S., Aimone L., Klein-Szanto A., Herbert J.M., Bono F., Schaeffer P., Casellas P., Bourie B., Pili R., Isaacs J., Ator M., Hudkins R., Vaught J., Mallamo J., Dionne C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003, 63:5978-5991.